| Literature DB >> 35488251 |
Chiara Antonini1, Sara Calandrini2,3, Fortunato Bianconi4.
Abstract
BACKGROUND: In Italy, the beginning of 2021 was characterized by the emergence of new variants of SARS-CoV-2 and by the availability of effective vaccines that contributed to the mitigation of non-pharmaceutical interventions and to the avoidance of hospital collapse.Entities:
Keywords: COVID-19; Conditional robustness analysis; Italy; ODE model
Mesh:
Substances:
Year: 2022 PMID: 35488251 PMCID: PMC9051820 DOI: 10.1186/s12879-022-07395-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.667
Fig. 1Flowchart of the computational workflow adopted to study the spread of COVID-19. The ODE model is calibrated against epidemiological data of COVID-19 through the Bayesian method CRC. Then, the CRA algorithm is applied in order to study the influence of infection and vaccination parameters on the hospitalization capacity. The main steps of the CRA are the following: (1) choice of an evaluation function representative of the property of interest, (2) perturbation of the parameter space with LHS, (3) model integration using the generated parameter vectors, (4) kernel density approach for estimating the conditional density of each model parameter. The final result is an index, called MIRI, which denotes the impact of the parameter on the chosen model observable
Fig. 2Graphic representation of the SEIRL-V model. Clinical stages for the population are: Susceptible (S), Exposed () where is the number of vaccine doses administered, Presymptomatic (), Asymptomatic (A), Recovered (R), Mild infection (M), Severe infection (H), Critical infection (ICU), Dead (D), Vaccinated 1st dose ( and Vaccinated 2nd dose ( The intervention measures are represented by L
Model parameters estimated by CRC for Italy using COVID-19 data from 1 September 2020 to 1 May 2021
| Parameter |
| 90th Percentile |
|---|---|---|
|
| 0.1342 | [0.1318–0.1721] |
|
| 0.2109 | [0.1833–0.214] |
|
| 0.2512 | [0.2393–0.3451] |
|
| 0.19 | [0.1366–0.205] |
|
| 0.0120 | [0.0112–0.0261] |
|
| 0.0516 | [0.0517–0.0677] |
|
| 0.0145 | [0.0112–0.0267 |
|
| 0.0253 | [0.0221–0.0283] |
|
| 0.005 | [0.0051–0.0057] |
|
| 0.007 | [0.0061–0.0073] |
|
| 0.0035 | [0.0031–0.0039] |
|
| 0.0048 | [0.0041–0.0049] |
|
| 0.4618 | [0.4529–0.4772] |
|
| 5.2668 | [5.1188–5.2792] |
|
| 9.8982 | [8.366–10.7008] |
|
| 14.5149 | [14.1736–15.7103] |
|
| 15.6204 | [15.0902–15.8961] |
|
| 12.6742 | [12.0992–12.8822] |
|
| 34.7989 | [33.4267–36.5895] |
|
| 25.3705 | [22.1059–25.5674] |
|
| 0.637 | [0.6033–0.6363] |
|
| 47.1717 | [46.4324–58.8729 |
|
|
| [ |
|
| 1.0409 | [1.0055–1.0442] |
|
| 0.3095 | [0.2653–0.369] |
|
| 0.2634 | [0.2099–03254] |
|
| 0.6842 | [0.612–0.7307] |
|
| 0.1837 | [0.1344–0.2704] |
The second and third column show, respectively, the mode vector of and the 90th percentile of the probability density function (pdf) of the parameter vector for Italy. Note that the pre-symptomatic period (PresymPeriod) is a percentage of the incubation period (IncubPeriod)
Rate values of the model obtained by combining parameter values in Table 1 with the formulas shown in Additional file 1
| Parameter | Value |
|---|---|
|
| 0.0028 |
|
| 0.523 |
|
| [0.0979, 0.0977, 0.0981, 0.0979] |
|
| [0.0031, 0.0033, 0.0029, 0.0031] |
|
| [0.0105, 0.0138, 0.0269, 0.0102] |
|
| 0.0162 |
|
| [0.0373, 0.034, 0.0209, 0.0376] |
|
| 0.0274 |
|
| 0.0515 |
|
| 0.4618 |
|
| 0,0688 |
Rates , , and have multiple values which derive from the variation of the fraction of patients in ICU (FracCritical, see Additional file 1)
Model parameters related to vaccination
| Parameter | Value |
|
|
|---|---|---|---|
|
| 240 days | 180 days | 540 days |
|
| 0.8 | 0.3 | 0.95 |
|
| 0.95 | 0.6 | 0.95 |
|
| 21 days | 21 days | 104 days |
|
| 0.808 | 0.3 | 0.95 |
|
| 0.946 | 0.6 | 0.95 |
The second column shows the nominal value of the parameter while the third and fourth columns report, respectively, the lower and upper boundaries of the sampling interval for parameter space perturbation in the CRA algorithm
Fig. 3Boxplot of MIRI values for the 10 realizations of the CRA. The evaluation function is the area under the curve of H
Fig. 4Boxplot of MIRI values for the 10 realizations of the CRA. The evaluation function is the area under the curve of ICU
Fig. 5Boxplot of MIRI values for the 10 realizations of the CRA. The evaluation function is the area under the curve of D
Different parameter setups for model simulation
| Scenario A | 1 | [180d,540d] | [0.5, 0.6, 0.7] | |
| 2 | [180d,540d] | [0.8, 0.9, 1] | ||
| 3 | [180d,540d] | [1.1, 1.2, 1.3] | ||
| Scenario B | 1 | [180d,540d] | [0.5, 1.5] | |
| 2 | [180d,540d] | [0.5, 1.5] | ||
| 3 | [180d,540d] | [0.5, 1.5] | ||
| Scenario C | 1 | 180d | [0.5, 1.5] | |
| 2 | 360d | [0.5, 1.5] | ||
| 3 | 540d | [0.5, 1.5] |
In Scenario A, parameters and are perturbed in the intervals shown below while parameter vector [,,] is fixed to three different values. In Scenario B and C parameters and are fixed, respectively. The unit of measurement for parameter is days (d)
Fig. 6Italy. Results of Scenario A: perturbation of parameters and . (a–c). Total number of hospitalization for three different values of [,,].(d–f). Total number of ICU patients for three different values of [,,].(g–i). Maximum number of deaths for three different values of [,,]. Data are normalized over the Italian population ( million) and multiplied by
Fig. 7Italy. Predicted scenarios for different values of vaccine efficacy against infection. Parameter , representing the efficacy of the first dose, is perturbed between 0.3 and 0.8 with a step size of 0.05. Parameter , representing the efficacy of the second dose, is perturbed between 0.6 and 0.95 with a step size of 0.035. Higher values of and correspond to higher color curves of H, ICU and D